Uncategorized
Clearside completes enrollment in phase 2 trial of CLS-TA for macular edema in noninfectious uveitis
Clearside Biomedical completed enrollment in a phase 2 clinical trial of CLS-TA using suprachoroidal space drug administration to treat macular edema associated with noninfectious uveitis, according to a press release. The phase 2 Dogwood trial to evaluate CLS-TA (triamcinolone acetonide) has a primary efficacy endpoint of mean change from baseline in retinal thickness at 2 months after treatment and secondary efficacy endpoints of visual acuity improvements at months 1 and 2 after treatment, the release said.